Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors.

(2017) A. W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

(2011) Bruno P Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Notch signaling: Emerging molecular targets for cancer therapy

(2010) Ling Yin et al.   BIOCHEMICAL PHARMACOLOGY

Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness

(2010) P Zhang et al.   ONCOGENE

Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation

(2009) M Tanaka et al.   BRITISH JOURNAL OF CANCER

Preclinical Profile of a Potent  -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

(2009) L. Luistro et al.   CANCER RESEARCH

Notch signaling contributes to the pathogenesis of human osteosarcomas

(2009) F. Engin et al.   HUMAN MOLECULAR GENETICS

Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood Ependymomas

(2009) Stéphanie Puget et al.   JOURNAL OF CLINICAL ONCOLOGY

Notch Signaling in Leukemia

(2008) Jon C. Aster et al.   Annual Review of Pathology-Mechanisms of Disease

Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis

(2008) P. Zhang et al.   CLINICAL CANCER RESEARCH

Molecular Characterization of the Pediatric Preclinical Testing Panel

(2008) G. Neale et al.   CLINICAL CANCER RESEARCH